Vericel Corp at JPMorgan Healthcare Conference Transcript
Hi, everyone. I'd like to welcome you to the third day of the JPMorgan Healthcare Conference. I'm [Elizabeth Yugata] I'm a member of the Investment Banking Healthcare team and it is my pleasure to introduce the CEO of Vericel, Nick Colangelo.
Great. Well, thank you, Elizabeth. It's great to be here today. And before we begin, as always, I just want to remind everyone that our presentation contains forward looking statements so you should refer to our documents on file with the SEC for further information.
So Vericel is a leading provider of advanced therapies in the sports medicine and severe burn care market. We combine innovations in biology with medical technologies to create a highly differentiated portfolio of advanced cell therapies and specialty biologics that repair tissue and restore lives. Our lead product is MACI, which is an advanced cell therapy that uses a patient's own cells to restore damaged cartilage and restore function. MACI become
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |